PT  - JOURNAL ARTICLE
AU  - Jiazhi Tang
AU  - Cheng Zhang
AU  - Paul Dalby
AU  - Frank Kozielski
TI  - The structure of the humanised A33 Fab C226S variant, an immunotherapy candidate for colorectal cancer
AID  - 10.1101/2022.06.21.497004
DP  - 2022 Jan 01
TA  - bioRxiv
PG  - 2022.06.21.497004
4099  - http://biorxiv.org/content/early/2022/06/21/2022.06.21.497004.short
4100  - http://biorxiv.org/content/early/2022/06/21/2022.06.21.497004.full
AB  - Colorectal cancer (CRC) causes the second highest cancer-related deaths worldwide. The human A33 antigen is a validated immunotherapy target, which is homogeneously expressed in 95% cases of primary and metastatic colorectal cancers. In this article, we report the structure of a humanised antigen-binding fragment A33 (A33 Fab), a therapeutic antibody candidate, in two different crystal forms. Insights into the structural features of A33 Fab are provided with a focus on the ‘grafted’ complementarity-determining regions (CDRs) and the switch linker between the variable and the constant regions.Synopsis The crystal structure of humanised A33 Fab, targeting colorectal cancer related antigen, was determined in two different space groups.Competing Interest StatementThe authors have declared no competing interest.